VivoSeq
Other

Minimal Residual Disease

0

Pipeline Programs↗

9

Active Trials↗

1

Companies Involved↗

Minimal Residual Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Eastern Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Terminated3 · 19%
Active, not recruiting3 · 19%
Recruiting3 · 19%
Not yet recruiting3 · 19%
Unknown status2 · 13%
Completed2 · 13%

Clinical Trials

Trial Activity

16 trials

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04991103·40 enrolled
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Recruiting·EEastern Cooperative Oncology Group·Phase 2·NCT05289687·20 enrolled
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT03965234·99 enrolled
Elimination of Minimal Residual Disease After Transplant
Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT05690984·30 enrolled
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05456698·31 enrolled
MInimal Residual Disease Adapted Strategy
Active, not recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT04934475·791 enrolled
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Not yet recruiting·TTongji Hospital·N/A·NCT07350824·276 enrolled
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
Not yet recruiting·GGuangdong Association of Clinical Trials·N/A·NCT06709274·342 enrolled
Minimal Residual Disease in Solid Malignancies
Not yet recruiting·EEuropean Institute of Oncology·N/A·NCT07268469·840 enrolled
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled
Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
Completed·TThe Institute of Molecular and Translational Medicine, Czech Republic·Phase 4·NCT02314871·60 enrolled
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01258933·4 enrolled
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
Terminated·UUniversity of Pennsylvania·Phase 2·NCT02935543·1 enrolled
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05601830·1 enrolled
Interferon α for the Therapy of Minimal Residual Disease
Unknown status·PPeking University People's Hospital·N/A·NCT02185261·81 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)